source
- Abbott reports 30‑day success in Tectonic trial of SonicForce coronary IVL systemAbbott announced that its investigational SonicForce Coronary IVL system achieved positive 30‑day outcomes in the Tectonic trial involving patients with severely calcified coronary artery disease.…
- Compass Pathways leads race for first psychedelic drug approval, non-profit rivalsCompass Pathways is widely viewed as a leading candidate to bring the first psychedelic medicine to market. The company has advanced its therapy through clinical development and is positioned near…